Resource

 

 

 

 

 

 

 

 

 

 

 

Banking & Finance - Capital Markets: Equity

Shearman & Sterling Advises ContraFect on its Initial Public Offering

06 Aug 2014

Shearman & Sterling represented ContraFect Corporation in connection with its initial public offering of 6,000,000 Units, with each Unit consisting of one share of common stock, one Class A Warrant to purchase one share of common stock and one Class B Warrant to purchase one-half share of common stock. The Units were sold to the public at a price of $6.00 per Unit for total gross proceeds of $36,000,000. The Units and their constituent securities are or will be listed on the Nasdaq Capital Market under the symbols “CFRXU,” “CFRX,” “CFRXW” and “CFRXZ.”

Paul Hastings Advises WH Group on US$2.36 Billion Hong Kong IPO

06 Aug 2014

Hong Kong - Paul Hastings, a leading global law firm, has announced that the firm represented WH Group Limited (“WH Group”, formerly known as Shuanghui International Holdings Limited) in its US$2.36 billion (HK$18.31 billion) global offering and IPO on the Main Board of the Hong Kong Stock Exchange (including the offering amount in the event that the over-allotment option is exercised in full). Morgan Stanley Asia Limited and BOCI Asia Limited acted as the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers of the offering.

Cross-Border Team Advises on Frankfurt IPO of Chinese Children’s Footwear Manufacturer

05 Aug 2014

A team from Squire Patton Boggs’ offices in China, Hong Kong, Germany, and Poland has advised Feike AG, the German holding of a leading manufacturer of children’s footwear and apparel in China, on its listing on the Frankfurt Stock Exchange. The public offering was conducted in Germany and Poland.

Allen & Overy advises syndicate banks on Braas Monier IPO

04 Aug 2014

Allen & Overy LLP advised the syndicate banks BNP Paribas, J.P. Morgan and UBS Investment Bank (joint global coordinators and joint bookrunners), as well as Berenberg and Goldman Sachs (joint bookrunners), on the initial public offering by chimney and rooftile manufacturer Braas Monier Building Group S.A. (Braas Monier).

At an issue price of EUR 24.00 per share, Braas Monier has a market capitalisation of approximately EUR 940 million.

Dechert Represents Tekla Healthcare Opportunities Fund (THQ) in IPO

04 Aug 2014

Tekla Capital Management LLC (Telka) announced yesterday the successful initial public offering (IPO) of Tekla Healthcare Opportunities Fund, a closed-end management investment company managed by Tekla. The Trust priced an offering of 38.5 million shares at a price of US$20.00 per share, for a total issuance of US$770 million. The total issuance may reach up to US$885 million should the underwriters exercise their over-allotment option in full, which may or may not occur. Shares commenced trading on the New York Stock Exchange on July 29, 2014 under the ticker symbol THQ.

Travers Smith acts on IPO of easyHotel

04 Aug 2014

Corporate partner Richard Spedding advised Investec Bank plc on the £30m AIM IPO of easyHotel plc. easyHotel is the international owner, developer, operator and franchisor of branded hotels. Its strategy is to target the "super budget" segment of the hotel industry.

Investec acted as sole bookrunner, broker and NOMAD to the issue. Admission and the commencement of unconditional dealings on the AIM market of the London Stock Exchange took place on 30 June 2014.

Linklaters advised Genfit on a capital increase by private placement of 49.7 million Euro

01 Aug 2014

Linklaters advised Genfit, a biotech company listed on Euronext Paris, on a capital increase by private placement realised on 20 June 2014.

The private placement was entirely placed with leading international investors, with the majority coming from the US, for an amount of 49.7 million Euro. The settlement-delivery of the new shares took place on 27 June 2014.

As the capital increase represents less than 10% of Genfit’s outstanding share capital, no prospectus has been established for the purpose of the listing of the shares on Euronext Paris.

Linklaters advised Innate Pharma on a capital increase of 50 million Euro reserved to specialised institutional investors

01 Aug 2014

Linklaters advised Innate Pharma, a biotech company listed on Euronext Paris, on a capital increase reserved to institutional investors specialised in biotech and pharmaceutical sectors realised on 23 June 2014.

The private placement was entirely placed with leading international investors for an amount of 50 million Euro. The settlement-delivery of the new shares took place on 26 June 2014.

Wragge Lawrence Graham & Co's Investment Funds team acts on six transactions which raise over £700 million in aggregate

01 Aug 2014

The highly rated Investment Funds team at Wragge Lawrence Graham & Co has over the past three months acted on seven high-profile transactions that have raised over £700 million in aggregate.

In May 2014 the team acted for existing client GCP Student Living PLC on its Open Offer, Placing and Offer for Subscription which raised £42 million.